Raadpleeg ook literatuurlijst niet-toxische stoffen en behandelingen specifiek bij darmkanker van arts-bioloog drs. Engelbert Valstar

Zie ook dit artikel in gerelateerde artikelen: 

https://kanker-actueel.nl/bewegen-sporten-en-lichamelijke-activiteit-naast-chemo-verbetert-sterk-tot-wel-47-procent-overall-overleving-van-operabele-darmkankerpatienten-stadium-iii.html

29 augustus 2019: Bron: Clinical Oncology

Wanneer darmkankerpatienten tijdens hun behandelingen veel lichamelijke activiteiten doen dan heeft dat invloed op de progressievrije ziekte die beduidend langer blijkt bij die patienten die per week 18 uur of meer lichamelijk actief zijn in vergelijking met patienten die minder dan 9 uur per week lichamelijk actief zijn.  Ook zijn er bij de patienten met veel lichamelijke activiteiten ook minder graad 3 bijwerkingen geconstateerd. De overall overleving was ook beter maar net niet statistisch significant.  (95% CI, 0.71 to 1.02; PTrend = .06)

Dit blijkt uit een deelstudie van de Cancer and Leukemia Group B (Alliance)/SWOG 80405 (ClinicalTrials.gov identifier: NCT00265850), a National Cancer Institute–sponsored phase III trial of systemic therapy for mCRC.

Het volledige studierapport: Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.  is tegen betaling in te zien.

Andere aan dit onderwerp gerelateerde artikelen van de redactie van Clinical Oncology zijn deze:

Hier het abstract van de recente studie:

 2019 Aug 13:JCO1901019. doi: 10.1200/JCO.19.01019. [Epub ahead of print]

Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.

Author information

1
Brigham and Women's Hospital, Boston, MA.
2
Dana-Farber/Partners CancerCare, Boston, MA.
3
Mayo Clinic, Rochester, MN.
4
University of California, San Francisco, San Francisco, CA.
5
Duke University, Durham, NC.
6
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.
7
University of North Carolina at Chapel Hill, Chapel Hill, NC.
8
Indiana University School of Medicine, Indianapolis, IN.
9
Medstar Washington Hospital Center, Washington, DC.
10
University of Chicago, Chicago, IL.
11
Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
12
Southeast Clinical Oncology Research Consortium, National Cancer Institute Community Oncology Research Program, Winston-Salem, NC.
13
West Virginia University Cancer Institute, Morgantown, WV.
14
SWOG, Portland, OR.
15
Oregon Health & Science University, Portland, OR.
16
Memorial Sloan Kettering Cancer Center, New York, NY.
17
Yale School of Medicine, New Haven, CT.

Abstract

PURPOSE:

Regular physical activity is associated with reduced risk of recurrence and mortality in patients with nonmetastatic colorectal cancer. Its influence on patients with advanced/metastatic colorectal cancer (mCRC) has been largely unexplored.

PATIENTS AND METHODS:

We conducted a prospective cohort study nested in Cancer and Leukemia Group B (Alliance)/SWOG 80405 (ClinicalTrials.gov identifier: NCT00265850), a National Cancer Institute-sponsored phase III trial of systemic therapy for mCRC. Within 1 month after therapy initiation, patients were invited to complete a validated questionnaire that reported average physical activity over the previous 2 months. On the basis of responses, we calculated metabolic equivalent task (MET) hours per week to quantify physical activity. The primary end point of the clinical trial and this companion study was overall survival (OS). Secondary end points included progression-free survival (PFS) and first grade 3 or greater treatment-related adverse events. To minimize confounding by poor and declining health, we excluded patients who experienced progression or died within 60 days of activity assessment and used Cox proportional hazards regression analysis to adjust for known prognostic factors, comorbidities, and weight loss.

RESULTS:

The final cohort included 1,218 patients. Compared with patients engaged in less than 3 MET hours per week of physical activity, patients engaged in 18 or more MET hours per week experienced an adjusted hazard ratio for OS of 0.85 (95% CI, 0.71 to 1.02; PTrend = .06) and for PFS of 0.83 (95% CI, 0.70 to 0.99; PTrend = .01). Compared with patients engaging in less than 9 MET hours per week, patients engaging in 9 or more MET hours per week experienced an adjusted hazard ratio for grade 3 or greater treatment-related adverse events of 0.73 (95% CI, 0.62 to 0.86; PTrend < .001).

CONCLUSION:

Among patients with mCRC in Cancer and Leukemia Group B (Alliance)/SWOG 80405, association of physical activity with OS was not statistically significant. Greater physical activity was associated with longer PFS and lower adjusted risk for first grade 3 or greater treatment-related adverse events.

PMID:
 
31408415
 
DOI:
 
10.1200/JCO.19.01019

Plaats een reactie ...

Reageer op "Lichamelijke activiteit door patienten met uitgezaaide gevorderde darmkanker geeft langere progressievrije ziekte en geeft minder graad 3 bijwerkingen tijdens de behandelingen."


Gerelateerde artikelen
 

Gerelateerde artikelen

Lichamelijke activiteit door >> Bewegen, sporten en lichamelijke >>